4.67 USD
+0.15 (+3.32%)
4.61 USD
-0.06 (-1.28%)
CVAC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. CVAC has an average financial health and profitability rating. CVAC has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CVAC was profitable.
CVAC had a negative operating cash flow in the past year.
CVAC had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CVAC reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 11.31%, CVAC belongs to the top of the industry, outperforming 93.96% of the companies in the same industry.
Looking at the Return On Equity, with a value of 14.79%, CVAC belongs to the top of the industry, outperforming 94.53% of the companies in the same industry.
The Return On Invested Capital of CVAC (14.12%) is better than 95.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROIC | 14.12% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CVAC's Profit Margin of 182.11% is amongst the best of the industry. CVAC outperforms 98.68% of its industry peers.
Looking at the Operating Margin, with a value of 212.01%, CVAC belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Gross Margin of CVAC (93.01%) is better than 93.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CVAC is creating value.
The number of shares outstanding for CVAC remains at a similar level compared to 1 year ago.
Compared to 5 years ago, CVAC has more shares outstanding
CVAC has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.21 indicates that CVAC is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.21, CVAC is doing good in the industry, outperforming 71.32% of the companies in the same industry.
CVAC has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
CVAC's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. CVAC outperforms 42.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.21 |
ROIC/WACC1.96
WACC7.21%
2.3 Liquidity
CVAC has a Current Ratio of 3.70. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
CVAC's Current ratio of 3.70 is in line compared to the rest of the industry. CVAC outperforms 44.91% of its industry peers.
A Quick Ratio of 3.69 indicates that CVAC has no problem at all paying its short term obligations.
CVAC has a Quick ratio (3.69) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
CVAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.83%, which is quite impressive.
CVAC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.98%.
CVAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.42% yearly.
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
3.2 Future
Based on estimates for the next years, CVAC will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
The Revenue is expected to decrease by -10.88% on average over the next years. This is quite bad
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 6.87 indicates a rather cheap valuation of CVAC.
Based on the Price/Earnings ratio, CVAC is valued cheaply inside the industry as 98.68% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.60, CVAC is valued rather cheaply.
CVAC is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.87 | ||
| Fwd PE | N/A |
4.2 Price Multiples
CVAC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CVAC is cheaper than 99.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.03 |
4.3 Compensation for Growth
CVAC's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
CVAC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
4.67
+0.15 (+3.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.45%
Inst Owner Change0%
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap1.05B
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts73.33
Price Target4.78 (2.36%)
Short Float %0.57%
Short Ratio0.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)557.4%
Min EPS beat(2)-39.67%
Max EPS beat(2)1154.47%
EPS beat(4)2
Avg EPS beat(4)282.88%
Min EPS beat(4)-39.67%
Max EPS beat(4)1154.47%
EPS beat(8)3
Avg EPS beat(8)141.82%
EPS beat(12)5
Avg EPS beat(12)87.36%
EPS beat(16)8
Avg EPS beat(16)76.39%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)0%
PT rev (3m)-2.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)404.74%
EPS NY rev (1m)9.31%
EPS NY rev (3m)2.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)34.82%
Revenue NY rev (1m)19.7%
Revenue NY rev (3m)20.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.87 | ||
| Fwd PE | N/A | ||
| P/S | 12.65 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.03 | ||
| P/tB | 1.06 | ||
| EV/EBITDA | 3.03 |
EPS(TTM)0.68
EY14.56%
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0.37
BVpS4.55
TBVpS4.42
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROCE | 16.62% | ||
| ROIC | 14.12% | ||
| ROICexc | 26.37% | ||
| ROICexgc | 27.79% | ||
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% | ||
| FCFM | N/A |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 28.09% | ||
| Cap/Sales | 7.01% | ||
| Interest Coverage | 66.45 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z | 4.21 |
F-Score3
WACC7.21%
ROIC/WACC1.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / CVAC FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 4 / 10 to CVAC.
Can you provide the valuation status for CUREVAC NV?
ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (CVAC). This can be considered as Overvalued.
How profitable is CUREVAC NV (CVAC) stock?
CUREVAC NV (CVAC) has a profitability rating of 5 / 10.
What is the financial health of CUREVAC NV (CVAC) stock?
The financial health rating of CUREVAC NV (CVAC) is 5 / 10.
What is the expected EPS growth for CUREVAC NV (CVAC) stock?
The Earnings per Share (EPS) of CUREVAC NV (CVAC) is expected to decline by -163.99% in the next year.